Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Mar;69(3):573–580. doi: 10.1172/JCI110483

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

C Korninger, O Matsuo, R Suy, J M Stassen, D Collen
PMCID: PMC371013  PMID: 7199539

Abstract

Extrinsic (tissue-type) plasminogen activator (plasminogen activator) was isolated either as a single-chain or as a two-chain molecule from the culture medium of a human melanoma cell line. The thrombolytic activity of both molecular forms of activator was investigated in beagle dogs with an experimental femoral vein thrombosis and compared with that of urokinase. The 125I-fibrinogen-labeled thrombus was formed in an isolated 4-cm segment of the vein, aged for 30 min, and the thrombolytic substances were infused over a 4-h period. The degree of thrombolysis was measured 2 h later as the difference between the injected and recovered 125I. In six control animals with a saline infusion the extent of thrombolysis was 16.3 +/- 3.8% (mean +/- SEM), in five dogs receiving 100,000 IU urokinase, 17.4 +/- 3.7% (P less than 0.4) and in four dogs with 1,000,000 IU urokinase 40.6 +/- 4.8% (P less than 0.001). Infusion of 100.000 IU single-chain plasminogen activator in five dogs resulted in 3.5 +/- 7.8% lysis (P less than 0.05) and of 100,000 IU two-chain plasminogen activator in five dogs in 60.1 +/- 10.8% (P less than 0.001). Infusion of 300,000 IU one-chain plasminogen activator yielded 57.5% lysis and of the same amount of two-chain plasminogen activator 72.9%. Significant activation of plasminogen, consumption of alpha 2-antiplasmin, and fibrinogen breakdown in plasma was only observed in animals receiving the high doses of urokinase but not in the saline, plasminogen activator, or the low-dose urokinase groups. It is thus concluded that in this thrombosis model human extrinsic plasminogen activator has a higher specific thrombolytic effect that urokinase. Plasminogen activator also appears to induce thrombolysis without systemic fibrinolytic activation and fibrinogen breakdown.

Full text

PDF
573

Images in this article

576Image
on p.576
577Image
on p.577

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki N., Von Kaulla K. N. The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Am J Clin Pathol. 1971 Feb;55(2):171–179. doi: 10.1093/ajcp/55.2.171. [DOI] [PubMed] [Google Scholar]
  2. Cole E. R., Bachmann F. W. Purification and properties of a plasminogen activator from pig heart. J Biol Chem. 1977 Jun 10;252(11):3729–3737. [PubMed] [Google Scholar]
  3. Edy J., De Cock F., Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Thromb Res. 1976 Apr;8(4):513–518. doi: 10.1016/0049-3848(76)90229-2. [DOI] [PubMed] [Google Scholar]
  4. FLETCHER A. P., ALKJAERSIG N., SHERRY S., GENTON E., HIRSH J., BACHMANN F. THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION. J Lab Clin Med. 1965 May;65:713–731. [PubMed] [Google Scholar]
  5. Fenton J. W., 2nd, Fasco M. J., Stackrow A. B. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977 Jun 10;252(11):3587–3598. [PubMed] [Google Scholar]
  6. Fitzgerald D. E., Frisch E. P. Continuous wave ultrasound evaluation of brinase treatment of chronic arterial obstruction. Angiology. 1974 Jul-Aug;25(7):444–448. doi: 10.1177/000331977402500703. [DOI] [PubMed] [Google Scholar]
  7. Genton E., Wolf P. S. Experimental pulmonary embolism: effects of urokinase therapy on organizing thrombi. J Lab Clin Med. 1967 Aug;70(2):311–325. [PubMed] [Google Scholar]
  8. Hume M. Urokinase evaluated with the experimental radioactive embolus. Thromb Diath Haemorrh. 1967 May 31;17(3-4):405–411. [PubMed] [Google Scholar]
  9. JOHNSON A. J., McCARTY W. R. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest. 1959 Sep;38:1627–1643. doi: 10.1172/JCI103941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kok P., Astrup T. Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Biochemistry. 1969 Jan;8(1):79–86. doi: 10.1021/bi00829a013. [DOI] [PubMed] [Google Scholar]
  11. Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981 Aug 28;46(2):561–565. [PubMed] [Google Scholar]
  12. Martin M., Roth F. J., Fiebach B. J., Auel H. Fibrinolytische Therapie mit Aktivator. Klinische Resultate, angiographische Befunde und Laboratoriumsergebnisse. Dtsch Med Wochenschr. 1978 Dec 8;103(49):1953–1957. doi: 10.1055/s-0028-1129375. [DOI] [PubMed] [Google Scholar]
  13. Matsuo O., Rijken D. C., Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost. 1981 Jun 30;45(3):225–229. [PubMed] [Google Scholar]
  14. Matsuo O., Rijken D. C., Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981 Jun 18;291(5816):590–591. doi: 10.1038/291590a0. [DOI] [PubMed] [Google Scholar]
  15. Merskey C., Lalezari P., Johnson A. J. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med. 1969 Jul;131(3):871–875. doi: 10.3181/00379727-131-33998. [DOI] [PubMed] [Google Scholar]
  16. Radcliffe R., Heinze T. Isolation of plasminogen activator from human plasma by chromatography on lysine-sepharose. Arch Biochem Biophys. 1978 Jul;189(1):185–194. doi: 10.1016/0003-9861(78)90131-5. [DOI] [PubMed] [Google Scholar]
  17. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  18. Rijken D. C., Wijngaards G., Zaal-de Jong M., Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta. 1979 Sep 29;580(1):140–153. doi: 10.1016/0005-2795(79)90205-8. [DOI] [PubMed] [Google Scholar]
  19. Smith R. A., Dupe R. J., English P. D., Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature. 1981 Apr 9;290(5806):505–508. doi: 10.1038/290505a0. [DOI] [PubMed] [Google Scholar]
  20. Strom O., Ollendorff P., Drewsen E., Tang P. Acute deep vein thrombosis treated with porcine plasmin. A double blind trial. Thromb Diath Haemorrh. 1974 Dec 31;32(2-3):468–482. [PubMed] [Google Scholar]
  21. Tytgat G. N., Collen D., Oei L. S., Van Damme B. Fibrinogen metabolism in healthy dogs and in dogs with CCl 4 -induced liver damage and with portal vein occlusion. Thromb Diath Haemorrh. 1972 Apr 30;27(2):319–336. [PubMed] [Google Scholar]
  22. VERMYLEN C., DE VREKER R. A., VERSTRAETE M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta. 1963 May;8:418–424. doi: 10.1016/0009-8981(63)90080-9. [DOI] [PubMed] [Google Scholar]
  23. Verhaeghe R., Verstraete M., Schetz J., Vanhove P., Suy R., Vermylen J. Clinical trial of brinase and anticoagulants as a method of treatment for advanced limb ischemia. Eur J Clin Pharmacol. 1979 Sep;16(3):165–170. doi: 10.1007/BF00562056. [DOI] [PubMed] [Google Scholar]
  24. Wiman B., Collen D. Molecular mechanism of physiological fibrinolysis. Nature. 1978 Apr 6;272(5653):549–550. doi: 10.1038/272549a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES